| 0000-00-00 |
|
|
|
External link to document |
| 2022-11-04 |
374 |
Stipulation-General (See Motion List for Stipulation to Extend Time) |
Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331 by Novartis Pharmaceuticals Corporation.… 29 October 2019
1:19-cv-02053
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2022-11-04 |
379 |
Order |
Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331. Signed by Judge Richard G. Andrews on 11… 29 October 2019
1:19-cv-02053
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2024-08-12 |
433 |
Order - Memorandum and Order |
quot;'134 patent"), 8,101,659 (the '"659 patent"),
and 8,796,331 (the '"…alleging infringement of U.S. Patent
Nos. 8,877,938 (the "'938 patent"), 9,388,134 (the "…quot;331 patent") by MSN and several other defendants. (D.I. 1). Only the '659
patent remains…DELAWARE
In re Entresto (SacubitrilNalsartan) Patent
…, 36, 51, 61, 70). This case is
one of several patent infringement actions filed by Novartis against |
External link to document |
| 2024-08-14 |
438 |
Redacted Document |
2023 opinion invalidating U.S. Patent No. 8,101,659 (“the ’659 Patent”) (MDL No.
20-2930-RGA, D.I. 1099… 2023 opinion invalidating U.S. Patent No. 8,101,659 (“the ’659 Patent”)
(MDL No. 20-2930-RGA, D.I. 1099…2930-RGA
In re Entresto (Sacubitril/Valsartan) Patent )
Litigation …-RGA, D.I. 402) and (2) the July 21, 2023 ’659
Patent Judgment (MDL No. 20-2930-RGA, D.I. 1120; C.A. …the July 7,
2023 opinion invalidating the ’659 Patent (MDL No. 20-2930-RGA, D.I. 1099; C.A. No. 19-
|
External link to document |
| 2024-08-20 |
441 |
Redacted Document |
5. In the Inter Partes Review of U.S. Patent 10,335,462 (Mylan Pharmaceuticals, Inc., et al. v. Novo…worldwide.7
9. U.S. Patent No. 8,101,659 (“the ’659 patent”) issued on January 24, 2012, and…conditions, among others.8 U.S. Patent No. 11,096,918 (“the ’918 patent”) issued on August 24,
2021, …Novartis combination patent appeal, or ongoing litigations involving other
patents, may be at risk of …on the ‘659 patent,
which was later held to be invalid. As Novartis notes, the ‘918 Patent is not eligible |
External link to document |
| 2024-08-20 |
443 |
Redacted Document |
.S. Patent No. 8,101,659 (“the ’659 patent”) against MSN, and that the validity of the ’659 patent
…659 and ’918 Patents and Nexus
45. Novartis’s counsel informs me that U.S. Patent 8,101,659 (“the ’659…659 patent. Novartis’s
counsel has also informed me that Novartis has asserted U.S. Patent No. …918
patent”) against MSN, and that the infringement and validity of the ’918 patent will be tried… Novartis noted that loss of patent exclusivity for one or more patented products – such as
Entresto |
External link to document |
